EA201290356A1 - Композиции для лечения тошноты и рвоты центрального происхождения - Google Patents

Композиции для лечения тошноты и рвоты центрального происхождения

Info

Publication number
EA201290356A1
EA201290356A1 EA201290356A EA201290356A EA201290356A1 EA 201290356 A1 EA201290356 A1 EA 201290356A1 EA 201290356 A EA201290356 A EA 201290356A EA 201290356 A EA201290356 A EA 201290356A EA 201290356 A1 EA201290356 A1 EA 201290356A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
treatment
vomits
chestnuts
central origin
Prior art date
Application number
EA201290356A
Other languages
English (en)
Other versions
EA026815B1 (ru
Inventor
Фабио Тренто
Серджо Кантореджи
Джорджия Росси
Роберта Каннелла
Даниеле Бонадео
Риккардо Бралья
Original Assignee
Хелсинн Хелткэа Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201290356(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Хелсинн Хелткэа Са filed Critical Хелсинн Хелткэа Са
Publication of EA201290356A1 publication Critical patent/EA201290356A1/ru
Publication of EA026815B1 publication Critical patent/EA026815B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Предоставляют композиции и способы лечения или предотвращения тошноты и рвоты у пациентов, подвергаемых химиотерапии, лучевой терапии или хирургическому лечению.
EA201290356A 2009-11-18 2010-11-18 Пероральная лекарственная форма, содержащая палоносетрон и нетупитант, капсульная лекарственная форма, способ лечения тошноты и рвоты EA026815B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US38270910P 2010-09-14 2010-09-14
PCT/IB2010/003106 WO2011061622A1 (en) 2009-11-18 2010-11-18 Compositions for treating centrally mediated nausea and vomiting

Publications (2)

Publication Number Publication Date
EA201290356A1 true EA201290356A1 (ru) 2012-12-28
EA026815B1 EA026815B1 (ru) 2017-05-31

Family

ID=43608757

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290356A EA026815B1 (ru) 2009-11-18 2010-11-18 Пероральная лекарственная форма, содержащая палоносетрон и нетупитант, капсульная лекарственная форма, способ лечения тошноты и рвоты

Country Status (39)

Country Link
US (1) US12042494B2 (ru)
EP (3) EP2727590B1 (ru)
JP (1) JP5890780B2 (ru)
KR (1) KR101615108B1 (ru)
CN (6) CN107050455B (ru)
AP (1) AP3083A (ru)
AU (1) AU2010320598B2 (ru)
BR (1) BR112012011485B1 (ru)
CA (1) CA2778301C (ru)
CL (1) CL2012001276A1 (ru)
CO (1) CO6551693A2 (ru)
CR (1) CR20120216A (ru)
CU (1) CU24048B1 (ru)
CY (1) CY1118062T1 (ru)
DK (2) DK2722045T3 (ru)
DO (1) DOP2012000138A (ru)
EA (1) EA026815B1 (ru)
EC (1) ECSP12011907A (ru)
ES (4) ES2494015T3 (ru)
GE (1) GEP20156226B (ru)
GT (1) GT201200156A (ru)
HK (2) HK1214147A1 (ru)
HR (3) HRP20140759T1 (ru)
HU (1) HUE029677T2 (ru)
IL (1) IL219576A (ru)
LT (1) LT2722045T (ru)
MA (1) MA33810B1 (ru)
MX (1) MX2012005347A (ru)
MY (1) MY159393A (ru)
NI (1) NI201200090A (ru)
NZ (1) NZ599439A (ru)
PE (1) PE20121483A1 (ru)
PL (3) PL2722045T3 (ru)
PT (2) PT2361090E (ru)
RS (2) RS55206B1 (ru)
SI (2) SI2722045T1 (ru)
SM (1) SMT201400112B (ru)
TN (1) TN2012000170A1 (ru)
WO (1) WO2011061622A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2494015T3 (es) 2009-11-18 2014-09-12 Helsinn Healthcare Sa Composiciones para tratar nauseas y vómitos de origen central
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
DK2744497T3 (en) * 2011-10-18 2016-08-01 Helsinn Healthcare Sa THERAPEUTIC COMBINATION OF netupitant AND palonosetron
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
EP3710000A1 (en) * 2017-11-17 2020-09-23 Vanda Pharmaceuticals Inc. Method of treatment of gastrointestinal diseases with tradipitant
AU2019215802A1 (en) * 2018-02-02 2020-07-23 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Oral formulations and uses thereof
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI98367C (fi) 1989-11-28 1997-06-10 Syntex Inc Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
HU230316B1 (hu) 2000-07-14 2016-01-28 F. Hoffmann-La Roche Ag N-oxidok, mint 4-fenil-piridin-származékok előgyógyszerei, eljárás és előállításukra és az ezeket tartalmazó gyógyszerkészítmények
DE60123661T2 (de) 2000-12-14 2007-08-16 F. Hoffmann-La Roche Ag Selbstemulgierende lipidmatrix (selm)
CA2505990C (en) 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
RU2373936C2 (ru) * 2003-04-08 2009-11-27 Проджиникс Фармасьютикалз, Инк. Применение метилналтрексона для лечения синдрома раздраженного кишечника
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007096763A2 (en) 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
UA97653C2 (ru) * 2006-10-24 2012-03-12 Хелсинн Хелткер С.А. Мягкие капсулы, содержащие палоносетрона гидрохлорид, которые имеют улучшенную стабильность и биологическую доступность
WO2009005673A1 (en) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
EP2247757A2 (en) * 2007-12-18 2010-11-10 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
ES2494015T3 (es) 2009-11-18 2014-09-12 Helsinn Healthcare Sa Composiciones para tratar nauseas y vómitos de origen central

Also Published As

Publication number Publication date
PL2722045T3 (pl) 2017-03-31
JP5890780B2 (ja) 2016-03-22
AU2010320598B2 (en) 2016-06-16
PL2722044T3 (pl) 2017-08-31
DK2361090T3 (da) 2014-08-25
AP3083A (en) 2015-01-31
NZ599439A (en) 2014-06-27
DK2722045T3 (en) 2016-10-24
HRP20161277T1 (hr) 2016-11-18
EP2722044B1 (en) 2017-01-04
ES2559475T3 (es) 2016-02-12
HK1214147A1 (zh) 2016-07-22
AU2010320598A1 (en) 2012-06-14
CY1118062T1 (el) 2017-06-28
US12042494B2 (en) 2024-07-23
US20230263799A1 (en) 2023-08-24
SI2361090T1 (sl) 2014-09-30
PT2361090E (pt) 2014-09-03
KR101615108B1 (ko) 2016-05-12
HUE029677T2 (hu) 2017-03-28
GEP20156226B (en) 2015-01-26
PT2722045T (pt) 2016-10-18
BR112012011485A2 (pt) 2018-04-03
EP2727590A1 (en) 2014-05-07
CN102655864A (zh) 2012-09-05
IL219576A (en) 2017-08-31
DOP2012000138A (es) 2012-11-15
SI2722045T1 (sl) 2017-02-28
CN106421793A (zh) 2017-02-22
ECSP12011907A (es) 2012-10-30
ES2623503T3 (es) 2017-07-11
KR20120101456A (ko) 2012-09-13
EP2361090B1 (en) 2014-05-21
AP2012006278A0 (en) 2012-06-30
WO2011061622A1 (en) 2011-05-26
CN104856999A (zh) 2015-08-26
CA2778301C (en) 2016-06-14
NI201200090A (es) 2012-11-13
EP2727590B1 (en) 2015-10-21
GT201200156A (es) 2014-03-27
PL2361090T3 (pl) 2014-10-31
SMT201400112B (it) 2014-11-10
BR112012011485B1 (pt) 2021-06-29
JP2013511507A (ja) 2013-04-04
CL2012001276A1 (es) 2012-12-07
CU20120078A7 (es) 2012-10-15
HRP20140759T1 (hr) 2014-10-24
CR20120216A (es) 2012-07-24
MX2012005347A (es) 2012-08-03
CA2778301A1 (en) 2011-05-26
MA33810B1 (fr) 2012-12-03
CN107050455A (zh) 2017-08-18
CU24048B1 (es) 2014-12-26
EA026815B1 (ru) 2017-05-31
MY159393A (en) 2016-12-30
PE20121483A1 (es) 2012-12-02
RS53491B1 (en) 2015-02-27
CN104856998A (zh) 2015-08-26
IL219576A0 (en) 2012-06-28
CN106512010A (zh) 2017-03-22
CN107050455B (zh) 2020-09-29
CO6551693A2 (es) 2012-10-31
CN106421793B (zh) 2023-06-16
ES2494015T3 (es) 2014-09-12
HK1214148A1 (zh) 2016-07-22
RS55206B1 (sr) 2017-01-31
LT2722045T (lt) 2016-09-26
HRP20170419T1 (hr) 2017-06-02
ES2595077T3 (es) 2016-12-27
EP2361090A1 (en) 2011-08-31
EP2722044A1 (en) 2014-04-23
TN2012000170A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
EA201290356A1 (ru) Композиции для лечения тошноты и рвоты центрального происхождения
UA107667C2 (ru) Лекарственные соединения, стимулирующие активность пируваткиназы-м2, композиции на их основе и применение при лечении рака
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
MX2019010601A (es) Terapia de combinacion para tratar cancer.
EA200970747A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX2017013142A (es) Terapia combinada para tratar cáncer.
MX350046B (es) Tratamientos para trastornos gastrointestinales.
DK2252322T3 (da) Vaccinesammensætninger
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
WO2009114703A3 (en) Combination therapy for the treatment of cancer
EA201100874A1 (ru) Соединения для лечения рака
EA201200428A1 (ru) Композиция и способ для лечения ожирения
EA201201338A1 (ru) Способы лечения комбинированных лучевых и тепловых поражений
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
EA201390925A1 (ru) Производные санглиферина и способы их получения
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
CY1115904T1 (el) Συνθεσεις και μεθοδοι για την προληψη και τη θεραπεια του βακτηριακου καψιματος

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent